These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 8299097

  • 1. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
    Mizutani Y, Yoshida O.
    Cancer; 1994 Feb 01; 73(3):730-7. PubMed ID: 8299097
    [Abstract] [Full Text] [Related]

  • 2. Overcoming tnf-alpha and cddp resistance of a human ovarian-cancer cell-line (c30) by treatment with buthionine sulfoximine in combination with tnf-alpha and or cddp.
    Mizutani Y, Bonavida B.
    Int J Oncol; 1993 Aug 01; 3(2):229-35. PubMed ID: 21573353
    [Abstract] [Full Text] [Related]

  • 3. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha.
    Mizutani Y, Bonavida B.
    Cancer; 1993 Aug 01; 72(3):809-18. PubMed ID: 8334635
    [Abstract] [Full Text] [Related]

  • 4. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.
    Mizutani Y, Bonavida B, Nio Y, Yoshida O.
    J Urol; 1994 Jun 01; 151(6):1697-702. PubMed ID: 8189599
    [Abstract] [Full Text] [Related]

  • 5. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX, Ogawa O, Kakehi Y.
    Int J Oncol; 2004 Jun 11; 24(6):1489-97. PubMed ID: 15138592
    [Abstract] [Full Text] [Related]

  • 7. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
    Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ.
    Cancer Res; 1993 Aug 15; 53(16):3662-6. PubMed ID: 8101766
    [Abstract] [Full Text] [Related]

  • 8. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine.
    Kang YJ.
    Toxicology; 1994 Mar 11; 88(1-3):177-89. PubMed ID: 8160199
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance.
    Safrit JT, Belldegrun A, Bonavida B.
    J Urol; 1993 May 11; 149(5):1202-8. PubMed ID: 8483246
    [Abstract] [Full Text] [Related]

  • 10. Pentoxifylline enhances sensitivity of a human ovarian cancer cell line (OVC-8) to TNF-alpha.
    Mizutani Y, Bonavida B.
    Biotherapy; 1993 May 11; 7(2):109-14. PubMed ID: 7803190
    [Abstract] [Full Text] [Related]

  • 11. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 12. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
    Lee KS, Kim HK, Moon HS, Hong YS, Kang JH, Kim DJ, Park JG.
    Korean J Intern Med; 1992 Jul 01; 7(2):111-7. PubMed ID: 1306072
    [Abstract] [Full Text] [Related]

  • 13. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis.
    Yokomizo A, Kohno K, Wada M, Ono M, Morrow CS, Cowan KH, Kuwano M.
    J Biol Chem; 1995 Aug 18; 270(33):19451-7. PubMed ID: 7642628
    [Abstract] [Full Text] [Related]

  • 14. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
    Bier H.
    Acta Otolaryngol; 1991 Aug 18; 111(4):797-806. PubMed ID: 1950544
    [Abstract] [Full Text] [Related]

  • 15. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ.
    Cell Mol Biol Res; 1995 Aug 18; 41(2):131-6. PubMed ID: 8581064
    [Abstract] [Full Text] [Related]

  • 16. [Augmentation of TNF- and lymphotoxin-mediated cytotoxic effect in the combined use of ACNU and involvement of oxygen free radicals].
    Matsunaga K, Mashiba H.
    Gan To Kagaku Ryoho; 1990 Mar 18; 17(3 Pt 2):452-8. PubMed ID: 2321976
    [Abstract] [Full Text] [Related]

  • 17. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Mar 18; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 18. Thiol regulation of the production of TNF-alpha, IL-6 and IL-8 by human alveolar macrophages.
    Gosset P, Wallaert B, Tonnel AB, Fourneau C.
    Eur Respir J; 1999 Jul 18; 14(1):98-105. PubMed ID: 10489835
    [Abstract] [Full Text] [Related]

  • 19. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.
    Lai GM, Ozols RF, Young RC, Hamilton TC.
    J Natl Cancer Inst; 1989 Apr 05; 81(7):535-9. PubMed ID: 2493524
    [Abstract] [Full Text] [Related]

  • 20. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance.
    Safrit JT, Bonavida B.
    Cancer Res; 1992 Dec 01; 52(23):6630-7. PubMed ID: 1330298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.